ERBB2 and breast carcinoma: The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines recommended that hormone receptors and HER2 are tested in tissue specimens obtained from recurrence or metastases in breast cancer patients [1–4].